This trial studies xisomab 3G3 to see how well it works in preventing blood clots in cancer patients with catheters.
1 Primary · 2 Secondary · Reporting Duration: From xisomab 3G3 infusion up to end of treatment visit (day 18)
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Xisomab 3G3 · No Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: